Bullfrog AI Holdings Inc
Bullfrog AI Holdings Inc is a healthcare diagnostics company that leverages artificial intelligence to develop diagnostic tools and services for the medical research and pharmaceutical sectors.
Business. Bullfrog AI Holdings Inc (BFRG.O) is a biotechnology and life-science tools company listed on the NASDAQ. The firm operates within the Health Care sector, focusing on the development and sale of biotechnology products. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the biotechnology and life-science tools market.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Bullfrog AI Holdings Inc (BFRG.O) has recorded new institutional holdings, marking a notable shift in its shareholder base. As of the most recent reporting periods, three distinct investors have added positions in the company. These additions were detected on June 20, 2026, and represent the first analysis for this ticker, meaning there is no prior basis for computing delta changes against previous holdings. The largest of these new positions was established by investor ID 465, who held 157,460 shares as of December 31, 2025. This stake was valued at approximately $0.14 million, representing a portfolio weight of roughly 0.0002%. This entry provides a baseline for institutional interest in the company’s equity during the latter part of 2025. Additional accumulation occurred in the first quarter of 2026. Investor ID 499 added 17,635 shares, valued at approximately $0.03 million, as of March 31, 2026. Simultaneously, investor ID 562 acquired 15,000 shares, also valued at roughly $0.03 million, by the same March 31, 2026 date. Both of these positions carry a portfolio weight of less than 0.001%. These new holdings contribute to Bullfrog AI’s current profile, which includes four top holders. The company currently has no listed officers, analyst coverage, or index memberships. The emergence of these specific institutional positions offers the initial data points for tracking ownership concentration and investor sentiment for BFRG.O.
Signals & dispatch
Composite-score breakdown
Synthesis
Bullfrog AI Holdings Inc (BFRG.O) is a biotechnology and life-science tools company listed on the NASDAQ. The firm operates within the Health Care sector, focusing on the development and sale of biotechnology products. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the biotechnology and life-science tools market.
Bullfrog AI has a strong liquidity position, with $2.18 million in cash and equivalents and no long-term debt, resulting in a debt-to-equity ratio of 0.0. The company's current ratio of 3.85 indicates that it has more than enough current assets to cover its current liabilities. However, the company's operating cash flow of -$5.52 million and free cash flow of -$6.49 million suggest significant cash outflows from operations.
The company's profitability metrics are negative, with a return on equity of -304.17% and a return on assets of -231.38%. These figures are well below the industry median for biotechnology and medical research firms, indicating that Bullfrog AI is not currently generating returns for its shareholders or assets. The company's operating income of -$6.59 million and net income of -$6.49 million further underscore its unprofitable operations.
Bullfrog AI's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. The lack of geographic diversification could expose the company to regional economic or regulatory risks, though the extent of this risk is not quantified in the available data.
The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The company's current revenue of $116.67 million is not compared to prior periods, making it difficult to assess its growth performance. The absence of a clear growth narrative is a concern for investors seeking to understand the company's long-term potential.
The risk assessment indicates that Bullfrog AI has low liquidity and dilution risk, with no immediate filing-based flags detected. The company's strong cash position and lack of long-term debt reduce the likelihood of near-term liquidity stress. However, the company's significant operating losses and negative cash flows from operations could increase the risk of future dilution if the company needs to raise additional capital. The company has not disclosed any recent equity issuances or dilution events in the available data.
There are no recent filings or transcripts available in the provided data to assess Bullfrog AI's strategic direction or operational developments. The absence of recent disclosures limits the ability to evaluate the company's response to market conditions or its progress on key initiatives.
Bullfrog AI Holdings Inc (BFRG.O) has recorded new institutional holdings, marking a notable shift in its shareholder base. As of the most recent reporting periods, three distinct investors have added positions in the company. These additions were detected on June 20, 2026, and represent the first analysis for this ticker, meaning there is no prior basis for computing delta changes against previous holdings. The largest of these new positions was established by investor ID 465, who held 157,460 shares as of December 31, 2025. This stake was valued at approximately $0.14 million, representing a portfolio weight of roughly 0.0002%. This entry provides a baseline for institutional interest in the company’s equity during the latter part of 2025. Additional accumulation occurred in the first quarter of 2026. Investor ID 499 added 17,635 shares, valued at approximately $0.03 million, as of March 31, 2026. Simultaneously, investor ID 562 acquired 15,000 shares, also valued at roughly $0.03 million, by the same March 31, 2026 date. Both of these positions carry a portfolio weight of less than 0.001%. These new holdings contribute to Bullfrog AI’s current profile, which includes four top holders. The company currently has no listed officers, analyst coverage, or index memberships. The emergence of these specific institutional positions offers the initial data points for tracking ownership concentration and investor sentiment for BFRG.O.
- Bullfrog AI has a strong liquidity position with $2.18 million in cash and no long-term debt.
- The company is unprofitable, with a return on equity of -304.17% and a return on assets of -231.38%.
- Bullfrog AI's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company has low liquidity and dilution risk, but its negative operating cash flows could increase the risk of future capital raises.
- There are no recent filings or transcripts available to assess the company's strategic direction or operational developments.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $0,63grant · 2026-06-11
- Director · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $0,63grant · 2026-06-11
- Director · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $0,63grant · 2026-06-11
- Director · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $1,43grant · 2025-09-25
- Director · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $1,43grant · 2025-09-25
- Director · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $1,43grant · 2025-09-25
- Director, Chief Executive Officer, 10% owner · Restricted Stock Units → Common StockAcquired 152 273grant · 2025-08-22
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Bullfrog AI Holdings Inc Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
Insider activity
- Chief Financial Officer · Common StockOther 4 950 · 2025-08-22
- Director · Common StockOther 5 710 · 2025-08-22
- Director · Common StockOther 2 813 · 2025-08-22
- Director, Chief Executive Officer, 10% owner · Common StockOther 75 000 · 2025-08-22
- Director · Common StockOther 5 710 · 2025-08-22
- Director · Common StockOther 2 813 · 2025-08-22
- Chief Financial Officer · Common StockOther 10 050 · 2025-08-22
- Director · Common StockOther 5 710 · 2025-08-22
- Director · Common StockOther 2 813 · 2025-08-22
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 25.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 7.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 1.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 8.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -19.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -57.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -49.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 14.3%Derived (calculated)
- Current ratio (FY 2025-12-31): 3.85xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.31xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -59.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 25.9%Derived (calculated)
- Net margin (FY 2025-12-31): -5,569.6%Derived (calculated)
- Gross margin (FY 2025-12-31): 18.8%Derived (calculated)
- Return on equity (FY 2025-12-31): -304.2%Derived (calculated)
- Return on assets (FY 2025-12-31): -231.4%Derived (calculated)
- Total operating expenses (annual): USD 6.62MSEC XBRL filing
- Cash & equivalents (annual): USD 2.18MSEC XBRL filing
- Total assets (annual): USD 2.81MSEC XBRL filing
- Shareholders' equity (annual): USD 2.14MSEC XBRL filing
- Current assets (annual): USD 2.58MSEC XBRL filing
- Total liabilities (annual): USD 672.02KSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- Revenue (annual): USD 116.67KSEC XBRL filing